---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-018765"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:28:33.363979+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports FY 2023 net loss $59.2M; positive fasedienol, itruvone clinical updates

## Summary
- Net loss of $59.2M for FY ended March 31, 2023, vs $48.7M prior year; cash $16.6M.
- Positive FDA feedback supports LSAS as primary endpoint for fasedienol Phase 3 FEARLESS program in SAD.
- Successful U.S. Phase 1 study of itruvone (PH10) enables Phase 2B development in MDD; Fast Track granted.
- PH80 nasal spray showed statistically significant reduction in hot flashes vs placebo in Phase 2A (p<.001).
- Company pursuing global partnerships to advance six CNS product candidates.

## SEC filing metadata
- accession: 0001437749-23-018765
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/0001437749-23-018765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/vtgn20230628_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-018765
- JSON: https://secwatch.observer/filing/0001437749-23-018765.json
- Plain text: https://secwatch.observer/filing/0001437749-23-018765.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported financial results for fiscal year ended March 31, 2023.
  - Period: fiscal year ended March 31, 2023
  - Result: reported results
  source text: today provided a corporate update and reported financial results for its fiscal year 2023 ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/0001437749-23-018765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.